Pharmacological Studies on Drug-Drug Interactions between Antidiabetic Drug (Glibenclamide) and Selective Anti-HIV Drug (Lamivudine) in Rats and Rabbits

Abstract

The studies were conducted in normal and diabetic rats, and in normal rabbits to find out the influence of lamivudine on pharmacodynamics of glibenclamide. Rats were divided into four groups each containing six. Group-I: treated with therapeutic dose (TD) of lamivudine (5.4mg/200g body weight). Group-II: treated with therapeutic dose of glibenclamide (0.18mg/200g body weight). Group-III: treated with combination of therapeutic dose of lamivudine and glibenclamide. Group-IV: served as control (acacia suspension l% w/v). Same grouping was done for multiple days of therapeutic dose (MTD) studies (10 days), double therapeutic dose (2TD) and multiple days of double therapeutic dose (M2TD) studies (10 days). Streptozotocin at a dose of 50mg/kg body weight intraperitoneally was used to induce diabetes. Rats with glucose levels more than 200mg/dL were considered as diabetic. The experiment was carried out as described for normal rats. The influence of combination of both the drugs was studied in normal rabbits. A group of normal rabbits were taken and the experiment was carried out as described for normal rats. The results indicate that lamivudine produced significant increase in blood glucose, thereby it alters the hypoglycaemic activity of glibenclamide in normal rats, diabetic rats as well as in normal rabbits. As the interaction has been found in two dissimilar species that is rats and rabbits it indicates, it may occur in humans also.